Agonists and antagonists at serotonin (5-hydroxytryptamine: 5-HT) receptors have gained access to the market for the two major variants of the irritable bowel syndrome (IRS), a functional disorder characterized by abdominal pain associated with diarrhoea and/or constipation in the absence of any organic abnormality. Indeed, the 5-HT3 receptor antagonist alosetron, withdrew from the market approximately two years ago for serious adverse gastrointestinal events, has returned this year on the US market with a narrowed indication related to the treatment of women with severe, diarrhoea-predominant IBS refractory to conventional IBS therapy. On the other hand, tegaserod, a partial 5-HT4 receptor agonist, has been recently approved hy the FDA for the treatment of women with constipation-predominant IBS. This review is mainly intended to discuss the role of neuronal and non-neuronal 5-HT in the pathophysiology of IBS and the mechanisms through which 5-HT3 and 5-HT4 receptors regulate visceral motility, perception and secretion.
Tonini M., Cipollina L., De Giorgio R., Barbara G., De Ponti F. (2002). Serotonergic drugs for the treatment of irritable bowel syndrome. JOURNAL OF FUNCTIONAL SYNDROMES, 2(2), 104-109.
Serotonergic drugs for the treatment of irritable bowel syndrome
De Giorgio R.;Barbara G.;De Ponti F.
2002
Abstract
Agonists and antagonists at serotonin (5-hydroxytryptamine: 5-HT) receptors have gained access to the market for the two major variants of the irritable bowel syndrome (IRS), a functional disorder characterized by abdominal pain associated with diarrhoea and/or constipation in the absence of any organic abnormality. Indeed, the 5-HT3 receptor antagonist alosetron, withdrew from the market approximately two years ago for serious adverse gastrointestinal events, has returned this year on the US market with a narrowed indication related to the treatment of women with severe, diarrhoea-predominant IBS refractory to conventional IBS therapy. On the other hand, tegaserod, a partial 5-HT4 receptor agonist, has been recently approved hy the FDA for the treatment of women with constipation-predominant IBS. This review is mainly intended to discuss the role of neuronal and non-neuronal 5-HT in the pathophysiology of IBS and the mechanisms through which 5-HT3 and 5-HT4 receptors regulate visceral motility, perception and secretion.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
